Cardiovascular and Metabolic Archives | Report Store

Diabetes and diabetic complications
Other metabolic diseases
Anemias
Hypertension
Thrombosis
Bleeding disorders
Cerebrovascular diseases
Heart failure
Ischemic heart disease

Sort by Price

Click to order products ascending

Display 15 Products per page

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

$599.00

This interview with a US key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies, diagnostic tools, and future treatment rates for the different fibrosis stages of NASH. Key pipeline assets highlighted include Ocaliva, elafibranor, cenicriviroc, and firsocostat.
May 20, 2019
Find out more
Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

$599.00

This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the different fibrosis stages of NASH.
May 20, 2019
Find out more
Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

$599.00

This reimbursement interview with a US key opinion leader (KOL) provides insight into pricing strategies, pricing barriers, and potential reimbursement criteria for non-alcoholic steatohepatitis therapies.
May 20, 2019
Find out more
Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast

$599.00

Key topics discussed in this specialist interview with a US-based key opinion leader (KOL) include the diagnostic landscape in NASH and future market trends, with a focus on GLP-1 agonists, FGF 19/21 analogs, and FXR agonists.
August 28, 2020
Find out more
Market Spotlight: Sickle Cell Anemia

$1,318.00

This Market Spotlight report covers the Sickle Cell Anemia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals.
March 17, 2022
Find out more
Market Spotlight: Duchenne Muscular Dystrophy (DMD)

$1,318.00

This Market Spotlight report covers the Duchenne Muscular Dystrophy (DMD) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, a 10-year disease prevalence forecast, probability of success, recent events and analyst opinion, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 10, 2022
Find out more
Market Spotlight: Amyloidosis

$1,318.00

This Market Spotlight report covers the Amyloidosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
April 14, 2022
Find out more
Market Spotlight: Coronary Artery Disease

$1,318.00

This Market Spotlight report covers the Coronary Artery Disease (CAD) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, and 10-year disease prevalence and incidence forecasts, as well as presenting drug-specific revenue forecasts.
February 17, 2022
Find out more
Market Spotlight: Obesity

$1,318.00

This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 14, 2022
Find out more
Market Spotlight: Acute Decompensated Heart Failure (ADHF)

$1,318.00

Approved drugs in the ADHF – preserved ejection fraction (acute HFpEF) space target natriuretic peptide receptors. These drugs are administered via the intravenous route.
March 25, 2022
Find out more
Market Spotlight: Chemotherapy-Induced Anemia

$1,318.00

This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 5, 2022
Find out more
Market Spotlight: Cold Agglutinin Disease

$1,318.00

Cold agglutinin disease (CAD) is a clonal B-cell lymphoproliferative disorder and a rare subgroup of autoimmune hemolytic anemia (AIHA). CAD accounts for 15–25% of AIHA and affects mainly middle aged or older individuals. The disease is characterized by the production of autoantibodies by bone marrow-derived clonal B cells which attach to erythrocytes when exposed to cold temperatures (0–4°C), causing agglutination and eventual immune-mediated hemolysis.
February 28, 2022
Find out more
Market Spotlight: Atrial Fibrillation

$1,318.00

This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Market Spotlight: Renal Disease

$1,318.00

This Market Spotlight report covers the Renal Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 10, 2022
Find out more
Market Spotlight: Venous Thromboembolism (VTE)

$1,318.00

This Market Spotlight report covers the Venous Thromboembolism (VTE) market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
February 18, 2022
Find out more

Cardiovascular and Metabolic

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast

Market Spotlight: Sickle Cell Anemia

Market Spotlight: Duchenne Muscular Dystrophy (DMD)

Market Spotlight: Amyloidosis

Market Spotlight: Coronary Artery Disease

Market Spotlight: Obesity

Market Spotlight: Acute Decompensated Heart Failure (ADHF)

Market Spotlight: Chemotherapy-Induced Anemia

Market Spotlight: Cold Agglutinin Disease

Market Spotlight: Atrial Fibrillation

Market Spotlight: Renal Disease

Market Spotlight: Venous Thromboembolism (VTE)